The potential role of bisphosphonates in prostate cancer

Skeletal morbidity secondary to metastases and osteoporosis is common in patients with advanced prostate cancer. Despite the typically sclerotic nature of prostate cancer metastases, osteoclast mediated osteolysis may play a significant role. This review addresses the newly recognised antitumour eff...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Prostate cancer and prostatic diseases 2002-01, Vol.5 (4), p.264-272
Hauptverfasser:	Oades, G M, Coxon, J, Colston, K W
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - blood supply Adenocarcinoma - complications Adenocarcinoma - drug therapy Adenocarcinoma - physiopathology Adenocarcinoma - secondary Angiogenesis Inhibitors - pharmacology Angiogenesis Inhibitors - therapeutic use Animals Anticancer properties Apoptosis - drug effects Biomedical materials Bisphosphonates Bone Density - drug effects Bone Neoplasms - blood supply Bone Neoplasms - complications Bone Neoplasms - drug therapy Bone Neoplasms - physiopathology Bone Neoplasms - secondary Bone resorption Bone Resorption - drug therapy Calcium - metabolism Complications and side effects Diphosphonates Diphosphonates - pharmacology Diphosphonates - therapeutic use Disease Progression Dosage and administration Drug therapy Homeostasis Humans Male Metastases Metastasis Morbidity Neovascularization, Pathologic - drug therapy Osteoclasts - drug effects Osteolysis Osteolysis - drug therapy Osteolysis - etiology Osteolysis - prevention & control Osteoporosis Osteoporosis - drug therapy Osteoporosis - etiology Osteoporosis - prevention & control Palliative Care Prevention Prostate cancer Prostatic Neoplasms - pathology Randomized Controlled Trials as Topic Rats Risk factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Skeletal morbidity secondary to metastases and osteoporosis is common in patients with advanced prostate cancer. Despite the typically sclerotic nature of prostate cancer metastases, osteoclast mediated osteolysis may play a significant role. This review addresses the newly recognised antitumour effects of bisphosphonates in addition to their role in inhibiting osteoclast mediated bone resorption. Both preclinical and clinical evidence of a role for bisphosphonates in the treatment and prevention of bone metastases secondary to prostate cancer is assessed.
ISSN:	1365-7852 1476-5608
DOI:	10.1038/sj.pcan.4500607